Verrica Pharmaceuticals
(NASDAQ) VRCA
Verrica Pharmaceuticals Financials at a Glance
Market Cap
$105.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$37.16M
Net Income (TTM)
-$17.83M
EPS (TTM)
-$1.03
P/E Ratio
-5.93
Dividend
$0.00
Beta (Volatility)
0.93 (Low)
Dividend
$0.00
Beta (Volatility)
0.93 (Low)
Price
$6.19
Volume
40,367.322
Open
$6.07
Price
$6.19
Volume
40,367.322
Open
$6.07
Previous Close
$6.13
Daily Range
$5.90 - $6.60
52-Week Range
$3.28 - $9.82
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
0.93 (Low)
Price
$6.19
Volume
40,367.322
Open
$6.07
Previous Close
$6.13
Daily Range
$5.90 - $6.60
52-Week Range
$3.28 - $9.82
Estimated Earnings Date
Aug 11, 2026
VRCA News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Verrica Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
76
CEO
Jayson M. Rieger, PhD, MBA
Website
www.verrica.comHeadquarters
West Chester, PA 19380, US
VRCA Financials
Key Financial Metrics (TTM)
Gross Margin
89.52%
Operating Margin
-36.39%
Net Income Margin
-47.97%
Return on Equity
-1136.50%
Return on Capital
-45.27%
Return on Assets
-45.96%
Earnings Yield
-16.86%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$105.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
17.18M
Volume
40.37K
Avg. Volume
68.78K
Financials (TTM)
Gross Profit
$33.27M
Operating Income
-$13.52M
EBITDA
-$11.36M
Operating Cash Flow
-$14.11M
Capital Expenditure
$0.00
Free Cash Flow
-$14.11M
Cash & ST Invst.
$20.60M
Total Debt
$1.44M
Verrica Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$5.02M
+46.1%
Gross Profit
$4.13M
+37.1%
Gross Margin
82.30%
N/A
Market Cap
$105.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$1.39M
N/A
Employees
76
N/A
Net Income
-$9.68M
+0.6%
EBITDA
-$9.33M
-27.2%
Quarterly Fundamentals
Total Cash
$20.60M
-30.4%
Total Debt
$1.44M
-96.6%
Accounts Receivable
$7.81M
+38.2%
Inventory
$1.97M
-19.7%
Long Term Debt
$698.00K
-97.6%
Short Term Debt
$744.00K
-94.5%
Return on Assets
-45.96%
N/A
Return on Invested Capital
-59.93%
N/A
Free Cash Flow
-$9.16M
+27.7%
Operating Cash Flow
-$9.16M
+27.7%